{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T06:35:58Z","timestamp":1776926158333,"version":"3.51.2"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>Transcatheter chemoembolization (TACE) combined with tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) shows promising efficacy in treating unresectable hepatocellular carcinoma (uHCC), but the specific patient population that would benefit most from this regimen remains unclear. This study aims to evaluate the prognoses of uHCC patients receiving triple therapy and develop a practical prognostic scoring model to identify those with the best beneficial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter retrospective study enrolled 270 uHCC patients who received first-line triple therapy across 20 centers. These participants were divided into the training (n=190) and external validation (n=80) cohorts. Treatment response was assessed by the modified Response Evaluation Criteria in Solid Tumors (mRECIST), and safety was evaluated via treatment-related adverse events (TRAEs) using National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE v5.0). Cox proportional hazards regression was used to identify independent prognostic factors for overall survival, which were utilized to develop the SAGES score; Kaplan-Meier curves and area under the receiver operating characteristic curve (AUC) were employed to validate the model\u2019s performance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the training cohort, the objective response rate was 47.9% and disease control rate was 63.2%. The median progression-free survival was 15.9 months, with 3-year overall survival and progression-free survival rates of 52.2% and 30.7%, respectively. Independent prognostic factors for poor overall survival included albumin-bilirubin grade 2\u20133, alpha-fetoprotein \u2265400 ng\/mL, maximum tumor size \u22658 cm, presence of extrahepatic metastasis, and absence of conversion surgery. Integrating these five factors, the SAGES score effectively stratified patients into low- (0\u20133 points), intermediate- (4\u20137 points), and high-risk (8\u201310 points) groups with significantly divergent survival outcomes in both cohorts (all p&amp;lt;0.001). The model exhibited robust discriminative ability, with AUCs of 0.78 in the training cohort and 0.75 in the validation cohort, outperforming individual prognostic factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Triple therapy showed promising clinical outcomes and the SAGES score provides reliable prognostic stratification and facilitates personalized treatment decisions for uHCC patients receiving this triple regimen.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1802427","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T05:36:45Z","timestamp":1776922605000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The SAGES scoring model leads to personalized treatment via the combination of TACE, TKIs and ICIs for unresectable hepatocellular carcinoma"],"prefix":"10.3389","volume":"17","author":[{"given":"Hesheng","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Guilin Medical University","place":["Guilin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueyao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, Second Affiliated Hospital of Guilin Medical University","place":["Guilin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhong","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital","place":["Nanning, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, First Affiliated Hospital of Guangxi Medical University","place":["Nanning, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaoping","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, Eighth Affiliated Hospital of Guangxi Medical University","place":["Guigang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanjian","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Wuzhou Red Cross Hospital","place":["Wuzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenfeng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, First People\u2019s Hospital of Yulin","place":["Yulin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ze","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, First People\u2019s Hospital of Nanning","place":["Nanning, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junjie","family":"Ou","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Wuzhou People\u2019s Hospital","place":["Wuzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peisheng","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, First People\u2019s Hospital of Qinzhou","place":["Qinzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongbing","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, Second Affiliated Hospital of Guilin Medical University","place":["Guilin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuqun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Guilin Medical University","place":["Guilin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.03.017","article-title":"Global burden of liver disease: 2023 update","volume":"79","author":"Devarbhavi","year":"2023","journal-title":"J Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.iliver.2024.100112","article-title":"Systematic treatment in unresectable hepatocellular carcinoma: The most concerns","volume":"3","author":"Zhong","year":"2024","journal-title":"Iliver"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.iliver.2025.100145","article-title":"Treatment for unresectable hepatocellular carcinoma patients: Options and management after complete response","volume":"4","author":"Wang","year":"2025","journal-title":"Iliver"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e18696","article-title":"First-line systemic treatment for hepatocellular carcinoma: A systematic review and network meta-analysis","volume":"9","author":"Ciliberto","year":"2023","journal-title":"Heliyon"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.engmed.2024.100037","article-title":"Transarterial chemoembolization for hepatocellular carcinoma: Treatment algorithm proposed by Chinese college of interventionalists (CCI)","volume":"1","author":"Zhu","year":"2024","journal-title":"EngMedicine"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00808","article-title":"Phase ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"513\u2013","DOI":"10.1200\/JCO.2020.38.4_suppl.513","article-title":"A phase ib study of lenvatinib (LEN) plus nivolumab (NIV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study 117","volume":"38","author":"Kudo","year":"2020","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2025.101664","article-title":"Impact of LEAP-012 and EMERALD-1 in the management of HCC","volume":"8","author":"Singal","year":"2026","journal-title":"Jhep Rep Innov Hepatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.14218\/JTG.2025.00008","article-title":"Clinical response to sequential HAIC and TAE combined with tislelizumab and lenvatinib treatment for hepatocellular carcinoma involving lung metastases: A case report","volume":"3","author":"Li","year":"2025","journal-title":"J Transl Gastroenterol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1109771","article-title":"Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/HEP.0000000000001229","article-title":"Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages","volume":"82","author":"Yang","year":"2025","journal-title":"Hepatology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1159\/000549844","article-title":"Prognostic usefulness of clinical complete response after PD-1 inhibitor-based combination therapy for unresectable hepatocellular carcinoma (GUIDANCE006)","author":"Ma","year":"2025","journal-title":"Liver Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2025.101587","article-title":"Prognostic value of radiological and pathological complete response following immune-based conversion therapy in patients with unresectable hepatocellular carcinoma (GUIDANCE004)","volume":"7","author":"Yang","year":"2025","journal-title":"Jhep Rep Innov Hepatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1159\/000546052","article-title":"Survival benefit of hepatectomy after complete or partial response to conversion therapy in unresectable hepatocellular carcinoma (GUIDANCE003): A multicenter study","volume":"14","author":"Yang","year":"2025","journal-title":"Liver Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.21972","article-title":"World medical association declaration of helsinki: Ethical principles for medical research involving human participants","volume":"333","year":"2025","journal-title":"JAMA"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1159\/000530495","article-title":"Guidelines for the diagnosis and treatment of primary liver cancer (2022 edition)","volume":"12","author":"Zhou","year":"2023","journal-title":"Liver Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1159\/000541249","article-title":"Consensus of Chinese experts on neoadjuvant and conversion therapies for hepatocellular carcinoma: 2023 update","volume":"14","author":"Bi","year":"2024","journal-title":"Liver Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jhep.2019.09.026","article-title":"mRECIST for HCC: Performance and novel refinements","volume":"72","author":"Llovet","year":"2020","journal-title":"J Hepatol"},{"key":"B22","volume-title":"Common terminology criteria for adverse events (CTCAE)","year":"2017"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-023-10613-x","article-title":"The TAE score predicts prognosis of unresectable HCC patients treated with TACE plus lenvatinib with PD-1 inhibitors","volume":"18","author":"Zeng","year":"2024","journal-title":"Hepatol Int"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-023-10502-3","article-title":"Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma","volume":"17","author":"Xin","year":"2023","journal-title":"Hepatol Int"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v29.i10.1614","article-title":"Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma","volume":"29","author":"Wang","year":"2023","journal-title":"World J Gastroenterol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.4003","article-title":"Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: A phase 3 randomized clinical trial","volume":"9","author":"Qin","year":"2023","journal-title":"JAMA Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1594935","article-title":"Matching-adjusted indirect comparison of tislelizumab plus lenvatinib versus sintilimab plus bevacizumab biosimilar as first-line treatment for unresectable hepatocellular carcinoma","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.02.032","article-title":"TREM2+ macrophages suppress CD8+ T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma","volume":"79","author":"Tan","year":"2023","journal-title":"J Hepatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"8669","DOI":"10.1007\/s00330-023-09754-2","article-title":"Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): A propensity score matching study","volume":"33","author":"Jin","year":"2023","journal-title":"Eur Radiol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.783236","article-title":"Strategies to improve the antitumor effect of immunotherapy for hepatocellular carcinoma","volume":"12","author":"Xing","year":"2021","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.848387","article-title":"Transarterial chemoembolization combined with lenvatinib plus PD-1 inhibitor for advanced hepatocellular carcinoma: A retrospective cohort study","volume":"13","author":"Cai","year":"2022","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040791","article-title":"Embolotherapeutic strategies for hepatocellular carcinoma: 2020 update","volume":"12","author":"Kishore","year":"2020","journal-title":"Cancers"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.1111\/cas.13806","article-title":"Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1\u20136 hepatocellular carcinoma model","volume":"109","author":"Kimura","year":"2018","journal-title":"Cancer Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s00535-025-02251-x","article-title":"Noninvasive prediction of the clinical benefit of immunotherapy in hepatocellular carcinoma","volume":"60","author":"Ono","year":"2025","journal-title":"J Gastroenterol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11101041","article-title":"TRANS-TACE: Prognostic role of the transient hypertransaminasemia after conventional chemoembolization for hepatocellular carcinoma","volume":"11","author":"Granito","year":"2021","journal-title":"J Pers Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02551-0","article-title":"Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): A multiregional, randomised, double-blind, placebo-controlled, phase 3 study","volume":"405","author":"Sangro","year":"2025","journal-title":"Lancet"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02575-3","article-title":"Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): A multicentre, randomised, double-blind, phase 3 study","volume":"405","author":"Kudo","year":"2025","journal-title":"Lancet"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1159\/000541539","article-title":"The impact of radiation dose and tumour burden on outcomes in hepatocellular carcinoma: 11-year experience in a 413-patient cohort treated with yttrium-90 resin microsphere radioembolisation","volume":"14","author":"Chen","year":"2024","journal-title":"Liver Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2024.101346","article-title":"Predictors of short- and long-term survival in unresectable hepatocellular carcinoma (uHCC) treated with transcatheter arterial chemoembolization combined with lenvatinib plus PD-1 inhibitors: A multicenter retrospective study","volume":"55","author":"Zeng","year":"2025","journal-title":"Lancet Reg Health - West Pac"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.709060","article-title":"Comprehensive treatment of trans-arterial chemoembolization plus lenvatinib followed by camrelizumab for advanced hepatocellular carcinoma patients","volume":"12","author":"Liu","year":"2021","journal-title":"Front Pharmacol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: A new evidence-based approach-the ALBI grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007366","article-title":"Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: A single-arm, phase II trial","volume":"11","author":"Zhang","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1159\/000528356","article-title":"Outcomes of salvage surgery for initially unresectable hepatocellular carcinoma converted by transcatheter arterial chemoembolization combined with lenvatinib plus anti-PD-1 antibodies: A multicenter retrospective study","volume":"12","author":"Wu","year":"2023","journal-title":"Liver Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.09.035","article-title":"Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score","volume":"76","author":"Scheiner","year":"2022","journal-title":"J Hepatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-020-07078-z","article-title":"The PPRD score stratifies patients with hepatocellular carcinoma and portal vein tumor thrombus treated with sorafenib plus transarterial chemoembolization","volume":"31","author":"Zhang","year":"2021","journal-title":"Eur Radiol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12865","article-title":"Risk prediction for patients with hepatocellular carcinoma undergoing chemoembolization: Development of a prediction model","volume":"36","author":"Kim","year":"2016","journal-title":"Liver Int Off J Int Assoc Study Liver"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1802427\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T05:36:45Z","timestamp":1776922605000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1802427\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":47,"alternative-id":["10.3389\/fimmu.2026.1802427"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1802427","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,23]]},"article-number":"1802427"}}